Peripartum Cardiomyopathy Reached Progressive Recovery Despites Poor Initial Ejection Fraction
Abstract
Peripartum cardiomyopathy (PPCM) is a pregnancy-associated, idiopathic cardiomyopathy secondary to marked left ventricular dysfunction, which manifests between the last month of pregnancy and the first five months postpartum. While it is relatively rare, PPCM is associated with significant morbidity and can be fatal. Its diagnosis is often delayed because its symptoms closely resemble those within the normal spectrum of pregnancy and the postpartum period. When PPCM is misdiagnosed or is not diagnosed in time, the consequences for patients could be deadly. We present a rare case which was first misdiagnosed but had a continuous progressive recovery of LV systolic function (LVSF) within five years after it was finally diagnosed and treated.
A 23 year-old female, P1A0, 8-weeks postpartum, was admitted to the emergency unit of our hospital because of dyspnea and fatigue, which developed three days after the delivery of her child. A week prior to delivery she was admitted to the hospital due to coughing, proteinuria and edema of her lower extremities. She was then diagnosed with severe preeclampsia. The patient, however, refused the administration of Magnesium-sulfate as a therapy because of personal reasons. 48 hours later, the patient was induced with oxytocin and she delivered a living female infant via vaginal delivery with no labor complications and was later discharged. Three days after delivery, the patient complained about having shortness of breath and fatigue. She went to a general practitioner who thought her symptoms were normal after a delivery. Two months later she went to an obstetric clinic for a check-up and was referred to the cardiology unit at our hospital. She stated that for the past two months, she had been experiencing symptoms such as exhaustion, palpitations, an inability to lay flat, decreased exercise tolerance and severe dyspnea.
PPCM is a rare but potentially lethal disease that remains a challenge to diagnose, prognosticate, and treat. It is increasingly recognized that the condition is often diagnosed late which may indicate a poor prognosis. However, there are cases in which the initial severity of left ventricular dysfunction or dilatation is not necessarily predictive for long-term functional outcome.
Downloads
References
2. Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM,Hosenpud JD, Ansari A, Baughman KL. Peripartum cardiomyopathy:National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183–1188.
3. Abboud J, Murad Y, Chen-Scarabelli C, Saravolatz L, Scarabelli TM. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol. 2007;Jun 12;118(3):295–303.
4. Demakis JG, Rahimtoola SH, Sutton GC, Meadows WR,
Szanto PB, et al. Natural course of peripartum cardiomyopathy.Circulation. 1971;44:1053-1061.
5. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, et al.
Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation.2005;111:2050-2055.
6. Barasa A, et al. Heart Failure in Late Pregnancy and Postpartum:Incidence and Long-Term Mortality in Sweden 1997-2010. J Card Fail. 2017.
7. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58:659-670.
8. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet.2006;368:687-693.
9. Amos AM, Jaber WA, Russell SD. Improved outcomes in
peripartum cardiomyopathy with contemporary. Am Heart J.
2006;152:509-513.
10. Hilfiker-Kleiner D, et al. Peripartum cardiomyopathy: Current management and future perspective. European Heart Journal.2015;36:1090–1097.
11. Moser M, Brown CM, Rose CH, Garovic VD. Hypertension
in pregnancy: is it time for a new approach to treatment? J Hypertens. 2012;30(6):1092–1100.
12. Givertz MM. Cardiology patient page: peripartum cardiomyopathy. Circulation. 2013;127:622-626.
13. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state ofknowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767–778.
14. Tibazarwa K, Lee G, Mayosi B, Carrington M, Stewart S, Sliwa K. The 12-lead ECG in peripartum cardiomyopathy. Cardiovasc J Afr. 2012;23(6):322–329.
15. Selle T, Renger I, Labidi S, Bultmann I, Hilfiker-Kleiner D. Reviewing peripartum cardiomyopathy: current state of knowledge. Future Cardiol. 2009;5(2):175-189.
16. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum
cardiomyopathy: a proof-of-concept pilot study. Circulation.2010;121(13):1465–1473.
17. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3):589–600.
18. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2002;4:305-309.
19. Bozkurt B, Villaneuva FS, Holubkov R, Tokarczyk T, Alvarez RJ Jr, MacGowan GA, Murali S, Rosenblum WD, Feldman AM, McNamara DM. Intravenous immune globulin in the therapy peripartum cardiomyopathy. J Am Coll Cardiol.
1999;34:177–180.
20. Bozkurt B, et al. Current diagnostic and treatment strategies forspecific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134:e579-e646.
21. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc.2005;80(12):1602-1606.
22. Chapa JB, Heiberger HB, Weinert L, Decara J, Lang RM, Hibbard JU. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol. 2005;105(6):1303-1308.
23. Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripartum cardiomyopathy.
Circ J. 2011;75(8):1975–1981.
24. Sliwa K, Förster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27(4):441–446.
25. Ravikishore AG, Kaul UA, Sethi KK, Khalilullah M. Peripartum cardiomyopathy: prognostic variables at initial evaluation. Int J Cardiol. 1991;32(3):377–380.
26. Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail. 008;10(9):861–868.
27. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001;344(21):1567-1571.
PDF downloads: 2521
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).








